BML-286 is a WNT pathway modulator with potential anticancer activity, inducing β-catenin- and TCF-dependent transcriptional activity, and can be used in the study of degenerative diseases, intestinal, breast, bladder, gastric, melanoma, leukemia, hepatocellular carcinoma and nephroblastoma.
Product detail